Neuropathic PainNCT07878429
BreEStim Pre-trial
A study testing Single-pulse BreEStim Treatment and Multiple-pulse BreEStim Treatment in people with Neuropathic Pain, run by The University of Texas Health Science Center, Houston at 1 site in United States.
Trial summary
The overall goal is to evaluate the effectiveness of different stimulation protocol of a novel intervention - Breathing-controlled electrical stimulation (BreEStim) in managing neuropathic pain after spinal cord injury (SCI). Read more about this study
- Who is it for?
- Ages 18 to 75 yearsHealthy volunteers can take part
- Conditions the study is for
- Neuropathic Pain
- What is being tested?
- Single-pulse BreEStim Treatment and Multiple-pulse BreEStim Treatment
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 32 participants
- Where
- 1 siteUnited States
- Study dates
- 19 Oct 2026to 29 Jan 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- has a history of SCI > 1 year;
- has a DN4 (Douleur Neuropathique en 4 questions)* score of 4 or greater;
- has an average pain score of 4 or more
- has neuropathic pain >3 months;
- is between 22 to 80 years of age;
- is stable on oral pain medications at least one month (no change in frequency and dosing of pain medications);
Show all 9Show fewer
- is able to tolerate BreEStim treatment for 1 minute.
- healthy;
- between 18-75 years old.
Who cannot join
- is on a mechanical ventilator;
- is currently having active urinary tract infection (UTI);
- does not have any residual sensation in the arms;
- has other pain (musculoskeletal, visceral etc.), but not neuropathic, e.g., shoulder pain from wheelchair use;
- has a pacemaker (to avoid possible side effect of electrical stimulation);
- is not able to follow commands, or to give consent;
Show all 16Show fewer
- has asthma or other pulmonary disease;
- has a history of cardiac pathology, implanted pacemakers, or current use of rhythm altering medication like beta-blockers;
- has a baclofen pump or deep brain implants;
- has a respiratory tract/sinus infection and rhinorrhea;
- has low motor neuron injury that no responses will be triggered by electrical stimulation;
- has severe mental disorders (e.g., depression, substance abuse) and is receiving active treatment and frequent monitoring;
- is not medically stable.
- Pregnancy
- individuals with neuromusculoskeletal impairments/injury or pain;
- women who are pregnant
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site
The University of Texas Health Science Center at Houston
Houston, Texas, 77030
Sheng Li, 713-797-7125, Sheng.Li@uth.tmc.edu
Shengai Li, 713-797-7561, Shengai.Li@uth.tmc.edu
About this study
Official title: A Randomized, Double-blind, Sham-controlled, Parallel-group Trial Designed to Evaluate the Efficacy of BreEStim in Managing Neuropathic Pain After SCI - a Pre-trial Study
The overall goal is to evaluate the effectiveness of different stimulation protocol of a novel intervention - Breathing-controlled electrical stimulation (BreEStim) in managing neuropathic pain after spinal cord injury (SCI).
- Conditions
- Neuropathic Pain
- Being tested
- Single-pulse BreEStim Treatment, Multiple-pulse BreEStim Treatment
- Keywords
- BreEStim, neuropathic pain
- Medical subject headings
- Neuralgia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Single-pulse BreEStim TreatmentDevice
During the Single-pulse BreEStim Treatment session, participants will remain relaxed while breathing is monitored using a nasal cannula. Surface electrodes will be placed over the median nerve at the wrist or another selected peripheral nerve. A single-pulse electrical stimulation will be synchronized with voluntary breathing and delivered at an individually tolerated intensity for approximately 30 minutes.
Multiple-pulse BreEStim TreatmentDevice
During the Multiple-pulse BreEStim Treatment session, participants will remain relaxed while breathing is monitored using a nasal cannula. Surface electrodes will be placed over the median nerve at the wrist or another selected peripheral nerve. Multiple-pulse electrical stimulation will be synchronized with voluntary breathing and delivered at an individually tolerated intensity for approximately 30 minutes.
| Study group | Role | What they receive |
|---|---|---|
| Single-pulse BreEStim Treatment, Then Multiple-pulse BreEStim Treatment | Experimental | Not described Receives: Device: Single-pulse BreEStim Treatment; Device: Multiple-pulse BreEStim Treatment |
| Multiple-pulse BreEStim Treatment, Then Single-pulse BreEStim Treatment | Experimental | Not described Receives: Device: Single-pulse BreEStim Treatment; Device: Multiple-pulse BreEStim Treatment |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Pain Level as Measured by the Visual Analog Scale (VAS).
VAS scores are recorded from 0 to 10 with 0 being "no pain" and 10 being "worst pain", a higher score indicating a higher level of pain. Change is reported as [(VAS score at baseline) - (VAS Score 10 minutes after intervention)] - a positive value indicates that the score (and pain level) decreased. Mean VAS difference will be compared.
Measured: Baseline, 10-15 minutes after intervention
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Oct 2026
- Study start19 Oct 2026 (estimated)
- Primary completion18 Dec 2026 (estimated)
- Study completion29 Jan 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Neuropathic PainStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 32 participants (estimated)
Sponsor and investigators
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Sponsor type
- University, hospital or other
- Collaborators
- National Institute of Neurological Disorders and Stroke (NINDS)
- Responsible party
- Principal investigator, Sheng Li, The University of Texas Health Science Center, Houston
- Investigators
- Sheng Li, MD, PhD, Principal investigator, The University of Texas Health Science Center, Houston
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07878429
- Sponsor's protocol ID
- HSC-MS-26-0892
- Other IDs
- UG3NS139014
- Status last verified
- Oct 2026
- First submitted
- 9 Oct 2026
- Last updated
- 20 Oct 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 20 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized, Double-blind, Sham-controlled, Parallel-group Trial Designed to Evaluate the Efficacy of BreEStim in Managing Neuropathic Pain After SCI - a Pre-trial Study
- ClinicalTrials.gov ID
- NCT07878429
- Acronym / sponsor ID
- HSC-MS-26-0892
- Conditions
- Neuropathic Pain
- Keywords
- BreEStim, neuropathic pain
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 32 participants (estimated)
- Lead sponsor
- The University of Texas Health Science Center, HoustonUniversity, hospital or other
- Collaborators
- National Institute of Neurological Disorders and Stroke (NINDS)
- Study start
- 19 Oct 2026 (estimated)
- Primary completion
- 18 Dec 2026 (estimated)
- Study completion
- 29 Jan 2027 (estimated)
- First posted
- 16 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The overall goal is to evaluate the effectiveness of different stimulation protocol of a novel intervention - Breathing-controlled electrical stimulation (BreEStim) in managing neuropathic pain after spinal cord injury (SCI).
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Single-pulse BreEStim Treatment, Then Multiple-pulse BreEStim Treatment | Experimental | Device: Single-pulse BreEStim Treatment, Device: Multiple-pulse BreEStim Treatment |
| Multiple-pulse BreEStim Treatment, Then Single-pulse BreEStim Treatment | Experimental | Device: Single-pulse BreEStim Treatment, Device: Multiple-pulse BreEStim Treatment |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (9 listed)
- has a history of SCI > 1 year;
- has a DN4 (Douleur Neuropathique en 4 questions)* score of 4 or greater;
- has an average pain score of 4 or more
- has neuropathic pain >3 months;
- is between 22 to 80 years of age;
Key exclusion criteria (16 listed)
- is on a mechanical ventilator;
- is currently having active urinary tract infection (UTI);
- does not have any residual sensation in the arms;
- has other pain (musculoskeletal, visceral etc.), but not neuropathic, e.g., shoulder pain from wheelchair use;
- has a pacemaker (to avoid possible side effect of electrical stimulation);
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Single-pulse BreEStim TreatmentDuring the Single-pulse BreEStim Treatment session, participants will remain relaxed while breathing is monitored using a nasal cannula. Surface electrodes will be placed over the median nerve at the wrist or another selected peripheral nerve. A single-pulse electrical stimulation will be synchronized with voluntary breathing and delivered at an individually tolerated intensity for approximately 30 minutes. | Device | Multiple-pulse BreEStim Treatment, Then Single-pulse BreEStim Treatment, Single-pulse BreEStim Treatment, Then Multiple-pulse BreEStim Treatment |
| Multiple-pulse BreEStim TreatmentDuring the Multiple-pulse BreEStim Treatment session, participants will remain relaxed while breathing is monitored using a nasal cannula. Surface electrodes will be placed over the median nerve at the wrist or another selected peripheral nerve. Multiple-pulse electrical stimulation will be synchronized with voluntary breathing and delivered at an individually tolerated intensity for approximately 30 minutes. | Device | Multiple-pulse BreEStim Treatment, Then Single-pulse BreEStim Treatment, Single-pulse BreEStim Treatment, Then Multiple-pulse BreEStim Treatment |
Primary outcome
Change in Pain Level as Measured by the Visual Analog Scale (VAS).
Time frame: Baseline, 10-15 minutes after intervention
VAS scores are recorded from 0 to 10 with 0 being "no pain" and 10 being "worst pain", a higher score indicating a higher level of pain. Change is reported as [(VAS score at baseline) - (VAS Score 10 minutes after intervention)] - a positive value indicates that the score (and pain level) decreased. Mean VAS difference will be compared.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Oct 2026.
- Individual participant dataSharing planned: No
Related trials for Neuropathic Pain
Not yet recruiting
Selective Nerve Root Block Versus Sham to Reduce Surgery for Lumbar Disc Herniation
Lumbar Disc Herniation, Lumbar Radiculopathy
Not yet recruitingObservational study
Twenty-five Years of Advanced RadioTherapy at San Raffaele Hospital
Malignant Tumor, Benign Neoplasm
RecruitingPhase 1/2
RP-008 in Combination With Daily Oral Varenicline for the Treatment of Trigeminal Neuralgia
Trigeminal Neuralgia
RecruitingPhase 2
Ultra-Early Gamma Knife Stereotactic Radiosurgery for TN
Trigeminal Neuralgia (TN)
Recruiting
Evaluation of the Effect of Adding Sodium Bicarbonate to Lidocaine in the Treatment of Myofascial Pain Syndrome
Myofacial Pain, Myofacial Pain Syndrome
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Sheng Li, MD, PhD principal investigator
The University of Texas Health Science Center, Houston
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Single-pulse BreEStim Treatment and Multiple-pulse BreEStim Treatment in people with Neuropathic Pain, run by The University of Texas Health Science Center, Houston at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 16 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 20 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Sheng Li, PhD ((713) 797-7125, Sheng.Li@uth.tmc.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Pain Level as Measured by the Visual Analog Scale (VAS). (time frame: Baseline, 10-15 minutes after intervention). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Oct 2026.